Table 2.

Cerebral blood flow in the global grey matter and predefined regions of interest by treatment and differences between treatments

Region	Darolutamide	Placebo	Enzalutamide	Placebo−darolutamide	Darolutamide−enzalutamide	Placebo−enzalutamide
	mL/100 g/min	mL/100 g/min	mL/100 g/min	% Difference	% Difference	% Difference
Primary endpoints (whole-brain grey matter)
Global grey meana	55.4	55.5	53.5	− 0.14	− 3.32	− 3.46
Temporo-occipitala	68.1	67.6	64.0	0.73	− 5.91b	− 5.22b
Secondary endpoints (predefined regions)
Anterior cingulate	66.4	66.0	64.1	0.71	− 3.59	− 2.89
L amygdala	51.6	51.4	50.3	0.31	− 2.44	− 2.13
R amygdala	50.5	50.9	49.0	− 0.70	− 3.02	− 3.70c
L dorsolateral prefrontal cortex	56.0	56.5	54.3	− 0.99	− 2.92	− 3.87c
R dorsolateral prefrontal cortex	58.0	57.4	55.5	1.00	− 4.39c	− 3.43
Dorsomedial prefrontal cortex	57.2	57.1	55.5	0.21	− 2.90	− 2.70
L ventrolateral prefrontal cortex	64.1	64.3	62.5	− 0.31	− 2.38	− 2.68
R ventrolateral prefrontal cortex	61.0	60.8	59.0	0.29	− 3.28	− 2.99
Ventromedial prefrontal cortex	63.3	62.8	61.0	0.79	− 3.58	− 2.80
L anterior hippocampus	51.2	50.9	49.6	0.64	− 3.12	− 2.50
R anterior hippocampus	49.3	49.6	48.2	− 0.73	− 2.28	− 2.98
L whole hippocampus	51.2	50.9	49.6	0.57	− 3.04	− 2.49
R whole hippocampus	48.9	49.2	47.6	− 0.59	− 2.57	− 3.15
L parahippocampal gyrus	50.4	50.3	48.8	0.36	− 3.17	− 2.82
R parahippocampal gyrus	48.6	49.1	47.7	− 0.97	− 1.79	− 2.73
L ventral striatum	57.2	57.4	55.8	− 0.34	− 2.46	− 2.78
R ventral striatum	57.1	57.7	56.1	− 0.89	− 1.83	− 2.70

Negative percentage difference values indicate a reduction in CBF following drug administration (i.e., placebo > drug); positive values indicate drug-related increases (i.e., drug > placebo) in CBF

CBF cerebral blood flow, FWE family-wise error, L left, R right

^aUsing voxel-based analysis of whole-brain grey matter

^bStatistically significant (pFWE < 0.05)

^cStatistically significant (p < 0.05 prior to Bonferroni correction for multiple comparisons)